相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Zinc-rs13266634 and the Arrival of Diabetes Pharmacogenetics: The Zinc Mystique
Nisa M. Maruthur et al.
DIABETES (2014)
Comparison of repaglinide and metformin monotherapy as an initial therapy in Chinese patients with newly diagnosed type 2 diabetes mellitus
Fu-Sheng Fang et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2014)
Zinc transport and diabetes risk
Ewan Pearson
NATURE GENETICS (2014)
Quantitative Assessment of the Effect of KCNJ11 Gene Polymorphism on the Risk of Type 2 Diabetes
Ling Qiu et al.
PLOS ONE (2014)
UCP2 transports C4 metabolites out of mitochondria, regulating glucose and glutamine oxidation
Angelo Vozza et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus
Rodolfo Guardado-Mendoza et al.
ARCHIVES OF MEDICAL SCIENCE (2013)
Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers
Yu Cheng et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Mitiglinide for type 2 diabetes treatment
Haley M. Phillippe et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
The diabetes-susceptible gene SLC30A8/ZnT8 regulates hepatic insulin clearance
Motoyuki Tamaki et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
NeuroD1 A45T and PAX4 R121W polymorphisms are associated with plasma glucose level of repaglinide monotherapy in Chinese patients with type 2 diabetes
Zhi-Cheng Gong et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide
Lisa Kitasato et al.
CARDIOVASCULAR DIABETOLOGY (2012)
KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese Type 2 diabetic patients
Xing-Ping Dai et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2012)
Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial
L. Li et al.
DIABETES OBESITY & METABOLISM (2012)
Repaglinide A Review of Its Use in Type 2 Diabetes Mellitus
Lesley J. Scott
DRUGS (2012)
IGF2BP2 and IGF2 genetic effects in diabetes and diabetic nephropathy
Tianwei Gu et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2012)
Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A
Veronica Y. Lang et al.
PHARMACOGENETICS AND GENOMICS (2012)
The Influence of MDR1 G2677T/A Genetic Polymorphisms on the Pharmacokinetics of Repaglinide in Healthy Chinese Volunteers
Qian Xiang et al.
PHARMACOLOGY (2012)
NAMPT-3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus
Fei-Feng Sheng et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2011)
Effects of KCNQ1 Polymorphisms on the Therapeutic Efficacy of Oral Antidiabetic Drugs in Chinese Patients With Type 2 Diabetes
W. Yu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Postprandial Blood Glucose Predicts Cardiovascular Events and All-Cause Mortality in Type 2 Diabetes in a 14-Year Follow-Up
Franco Cavalot et al.
DIABETES CARE (2011)
Additive hypoglycaemic effect of nateglinide and exogenous glucagon-like peptide-1 in type 2 diabetes
P. M. Bell et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2011)
UCP2-866G/A and Ala55Val, and UCP3-55C/T polymorphisms in association with type 2 diabetes susceptibility: a meta-analysis study
K. Xu et al.
DIABETOLOGIA (2011)
Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers
Jiake He et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2011)
IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population
Qiong Huang et al.
ACTA PHARMACOLOGICA SINICA (2010)
A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese
Wen Qin et al.
ACTA PHARMACOLOGICA SINICA (2010)
Mitiglinide: A Novel Agent for the Treatment of Type 2 Diabetes Mellitus
Haley M. Phillippe et al.
ANNALS OF PHARMACOTHERAPY (2010)
KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) Polymorphisms Affect Therapeutic Efficacy of Repaglinide in Chinese Patients With Type 2 Diabetes
M. Yu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Association of genetic variants of NOS1AP with type 2 diabetes in a Chinese population
C. Hu et al.
DIABETOLOGIA (2010)
NOS1AP variant associated with incidence of type 2 diabetes in calcium channel blocker users in the Atherosclerosis Risk in Communities (ARIC) study
A. Y. Chu et al.
DIABETOLOGIA (2010)
Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis
Masanori Abe et al.
ENDOCRINE JOURNAL (2010)
Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients
Qiong Huang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis
Masanori Abe et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
CYP3A4 Genetic Polymorphism Influences Repaglinide's Pharmacokinetics
A. B. Ruzilawati et al.
PHARMACOLOGY (2010)
A Variant in the KCNQ1 Gene Predicts Future Type 2 Diabetes and Mediates Impaired Insulin Secretion
Anna Jonsson et al.
DIABETES (2009)
Variations in KCNQ1 are associated with type 2 diabetes and beta cell function in a Chinese population
C. Hu et al.
DIABETOLOGIA (2009)
Persistent Oxidative Stress Due to Absence of Uncoupling Protein 2 Associated with Impaired Pancreatic β-Cell Function
Jingbo Pi et al.
ENDOCRINOLOGY (2009)
IGF2 mRNA-binding protein 2: biological function and putative role in type 2 diabetes
Jan Christiansen et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2009)
Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients
Ya-yi He et al.
ACTA PHARMACOLOGICA SINICA (2008)
The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range
Annikka Kalliokoski et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Common variants in CDKAL1, CDKN2A/B, IGF2BP2, SLC30A8, and HHEX/IDE genes are associated with type 2 diabetes and impaired fasting glucose in a Chinese Han population
Ying Wu et al.
DIABETES (2008)
Implication of genetic variants near TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO in type 2 diabetes and obesity in 6,719 Asians
Maggie C. Y. Ng et al.
DIABETES (2008)
Interaction of oral antidiabetic drugs with hepatic uptake transporters -: Focus on organic anion transporting polypeptides and organic cation transporter 1
Louri Bachmakov et al.
DIABETES (2008)
Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
Annikka Kalliokoski et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus
Kazuki Yasuda et al.
NATURE GENETICS (2008)
SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations
Hiroyuki Unoki et al.
NATURE GENETICS (2008)
Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism
C. Rodriguez-Antona et al.
PHARMACOGENOMICS JOURNAL (2008)
Nampt/PBEF/Visfatin regulates insulin secretion in β cells as a systemic NAD biosynthetic enzyme
Javier R. Revollo et al.
CELL METABOLISM (2007)
Direct effect of cholesterol on insulin secretion -: A novel mechanism for pancreatic β-cell dysfunction
Mingming Hao et al.
DIABETES (2007)
Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes -: Importance of postprandial glycemia to achieve target HbA1c levels
Hans J. Woerle et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2007)
Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: Nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1
Nicola A. Duffy et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Role of OATP transporters in the disposition of drugs
Mikko Niemi
PHARMACOGENOMICS (2007)
Improvement of insulin sensitivity and β-cell function by nateglinide and repaglinide in type 2 diabetic patients -: a randomized controlled double-blind and double-dummy multicentre clinical trial
J. Li et al.
DIABETES OBESITY & METABOLISM (2007)
The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals
Javier R. Revollo et al.
CURRENT OPINION IN GASTROENTEROLOGY (2007)
A genome-wide association study identifies novel risk loci for type 2 diabetes
Robert Sladek et al.
NATURE (2007)
Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases
Lushan Yu et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide
Wei Zhang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide
TB Bidstrup et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Effects of IKs channel inhibitors in insulin-secreting INS-1 cells
S Ullrich et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2005)
Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients
R Assaloni et al.
DIABETOLOGIA (2005)
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics
M Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Type 2 diabetes: principles of pathogenesis and therapy
M Stumvoll et al.
LANCET (2005)
Organic anion transporting polypeptides of the OATP/SLC21 family:: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties
B Hagenbuch et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2004)
Polymorphisms of the SUR1 (ABCC8) and Kir6.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to type 2 diabetes.: The Finnish diabetes Prevention Study
O Laukkanen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
M Niemi et al.
PHARMACOGENETICS (2004)
The-866A/A genotype in the promoter of the human uncoupling protein 2 gene is associated with insulin resistance and increased risk of type 2 diabetes
M D'Adamo et al.
DIABETES (2004)
Repaglinide versus nateglinide monotherapy - A randomized multicenter study
J Rosenstock et al.
DIABETES CARE (2004)
Postprandial glucose regulation and diabetic complications
A Ceriello et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
Clinical pharmacokinetics of nateglinide - A rapidly-absorbed, short-acting insulinotropic agent
JF McLeod
CLINICAL PHARMACOKINETICS (2004)
Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers
J Kirchheiner et al.
CLINICAL PHARMACOKINETICS (2004)
Polymorphism in CΥP2C8 is associated with reduced plasma concentrations of repaglinide
M Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide
TB Bidstrup et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Clinical significance, pathogenesis, and management of postprandial hyperglycemia
JE Gerich
ARCHIVES OF INTERNAL MEDICINE (2003)
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes:: Consequences for pravastatin pharmacokinetics
Y Nishizato et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients -: Variations with increasing levels of HbA1c
L Monnier et al.
DIABETES CARE (2003)
KCNQ1 gain-of-function mutation in familial atrial fibrillation
YH Chen et al.
SCIENCE (2003)
Fasting and postchallenge glycemia and cardiovascular disease risk - The framingham offspring study
JB Meigs et al.
DIABETES CARE (2002)
Section 2: Biphasic insulin release: Pools and signal modulation - Modeling phasic insulin release - Immediate and time-dependent effects of glucose
R Nesher et al.
DIABETES (2002)
Phasic insulin release and metabolic regulation in type 2 diabetes
S Del Prato et al.
DIABETES (2002)
Clinical pharmacokinetics and pharmacodynamics of repaglinide
V Hatorp
CLINICAL PHARMACOKINETICS (2002)
Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence
E Bonora et al.
DIABETOLOGIA (2001)
A missense mutation of Pax4 gene (R121W) is associated with type 2 diabetes in Japanese
Y Shimajiri et al.
DIABETES (2001)
A neuronal isoform of nitric oxide synthase expressed in pancreatic β-cells controls insulin secretion
AD Lajoix et al.
DIABETES (2001)
Repaglinide - A review of its therapeutic use in type 2 diabetes mellitus
CR Culy et al.
DRUGS (2001)
Meglitinide analogues in the treatment of type 2 diabetes mellitus
R Landgraf
DRUGS & AGING (2000)
分享论文
